PTIX - יחס חוב להיוון בספרים protagenic.com

Protagenic Therapeutics (PTIX) enjoys steady confidence from neurobiologists and investors due to its clinical successes. The business relies on developing treatments for PTSD and depression that are covered by insurance companies. Unique peptide patents and strict FDA oversight serve as defensive assets. This chart of the total debt-to-book capitalization ratio demonstrates the financing structure, and 0.00 captures the current value of the indicator.

Investors use this ratio to assess the issuer's solvency and debt risk level. The metric compares total liabilities to the book value of equity, determining the business's degree of dependence on borrowed funds. The trend in the financial stability indicator—debt-to-capitalization—reveals hidden leverage fluctuations between quarterly reports. For Protagenic Therapeutics (PTIX), this confirms the effectiveness of strict control over R&D expenses. The biotech company's qualified management minimizes financial gaps, ensuring transparency in the capital structure.